
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Stasis dermatitis is a red, itchy, scaly rash that develops on the lower legs as a result of leakage of fluid from the blood vessels.